Echosens
Quick, Reliable, and Non-Invasive Gold Standard of Liver Monitoring

On a worldwide basis, liver health has remained an unmet medical need. The liver is an organ that many people are unfamiliar with. Even though it is an essential organ, humans may be unaware of the importance of liver health. Chronic liver disease is on the rise, but it is treatable if detected early and properly monitored and treated. Preventing cirrhosis by treating individuals at pre-cirrhotic stages of illness is one of the therapeutic goals. However, in the early stages of liver disease, every currently known technique for determining disease severity is insufficiently accurate. Current techniques are unable to track natural development or assess therapy or intervention efficacy related to a liver. To meet these needs non-invasive devices with accurate monitoring are being developed by med-tech companies. And leading these firms is Echosens; a pioneer in its field it significantly changed the practice of liver diagnosis with FibroScan, the non-invasive gold standard solution for comprehensive management of liver health.

Echosens has developed various FibroScan devices depending on the required diagnosis of a liver. The Products in the FibroScan® range are Class IIa medical devices, which are used in medical practices to measure liver stiffness and ultrasound attenuation in patients with liver disease. The range of Fibroscan devices is equipped with LSM by VCTE, spleen stiffness measurement (SSM) by VCTE and CAP which are unique, patented and validated methods of liver assessment. The FibroScan devices range from a portable scanner to a pushcart monitoring device, which is used for various diagnoses of liver assessment.

The FibroScan Mini 430 is a mobile non-invasive solution powered by LSM by VCTE for liver fibrosis assessment, it is designed for multi-centre sharing and remote liver patient management. Succeeding the Mini 430 is the FibroScan Mini 430+, it is ideal for multi-site configuration, and it is supported by LSM by VCTE and CAP for liver fibrosis and liver steatosis assessment.

The other device which assists in the assessment of steatosis is FibroScan Compact 530 which is backed by LSM by VCTE and CAP to provide efficient results.

With its optional roll stand, 15” interactive touch screen display and durable ergonomic design, FibroScan®Compact 530 is the perfect liver assessment solution for any point-of-care setting. As a complete non-invasive solution, the FibroScan Expert 630 is used for monitoring advanced liver diseases. The device is powered by LSM by VCTE, CAP and SSM by VCTE for liver fibrosis, liver steatosis and portal hypertension assessment. With the new SSM by VCTE and the embedded ultrasound localization, the system enables risk stratification of patients with advanced chronic liver disease and portal hypertension.

Furthermore, Scores by Echosens combines FibroScan® results with other parameters to get the best performance and better monitoring of patients. Just like the FibroScan’s range of devices, the Scores also has three different options. FibroScan-based Score Fast combines FibroScan® examination results (LSM by VCTE & CAP) with an easily accessible blood biomarker (AST) to help identify patients with active fibrotic-NASH, at the point-of-care, reducing invasive and costly procedures.

The next on the list is Agile 3+, which aids in the identification of advanced fibrosis in NAFLD patients. Agile 3+ combines LSM by VCTE with easily accessible blood biomarkers (AST, ALT, Platelets) to help in the identification of advanced fibrosis patients with optimized positive predictive values compared to LSM alone and help in the prediction of liver complications. Aiding with the identification of cirrhosis in NAFLD patients is Score: Agile 4, which proactively manages the disease through screenings for liver-related complications such as hepatocellular carcinoma and oesophageal varices and helps patients. To top It all Echosens Scores can be monitored remotely through the Echosens myFibroScan application.

With over 2,500 peer-reviewed papers and 70 international guidelines, the company’s FibroScan is widely regarded as the gold standard for assessing liver fibrosis and steatosis. Echosens sees a future in which every medical practitioner has the tools they need to assess liver health, detect diseases, and manage therapies in a simple, accurate, and efficient manner. Echosens develops these solutions for the benefit of patients using its abilities, competences, and enthusiasm for innovation and technology.